Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients

NCT00255177 is registered in ClinicalTrials.gov with VGX Pharmaceuticals, LLC as lead sponsor.

NCT NCT00255177
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00255177 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients
Lead sponsor
VGX Pharmaceuticals, LLC
Phase
Phase 2
Overall status
Completed
Start date
November 30, 2005
Completion date
January 31, 2008
Enrollment
44 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

hepatitis c virus infection